Modern Retina articleshttps://www.modernretina.com/newsModern Retina articles© 2026 MJH Life Sciences™ and Modern Retina. All rights reserved.Sun, 19 Apr 2026 05:11:28 +00005en-us14447https://www.modernretina.com/newshttps://www.modernretina.com/logo.webphttps://www.modernretina.com/view/the-retina-tl-dr-with-dr-weng-unpacking-photobiomodulation-for-dry-amdhttps://www.modernretina.com/view/the-retina-tl-dr-with-dr-weng-unpacking-photobiomodulation-for-dry-amd<![CDATA[In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Drs. Do, Lad, and Munk about the LIGHTSITE III trial data behind photobiomodulation and what it means for retina practice.]]>Thu, 16 Apr 2026 16:00:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/eclipse-life-sciences-completes-enrollment-in-bettis-1-phase-2-clinical-trialhttps://www.modernretina.com/view/eclipse-life-sciences-completes-enrollment-in-bettis-1-phase-2-clinical-trial<![CDATA[The trial will evaluate EC-104 fluocinolone acetonide (FA) extended release for the treatment of diabetic macular edema (DME).]]>Wed, 15 Apr 2026 10:01:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/new-tried-and-true-treatments-for-retinal-vein-occlusionhttps://www.modernretina.com/view/new-tried-and-true-treatments-for-retinal-vein-occlusion<![CDATA[Explore latest RVO care: faricimab, Eylea HD, and biosimilars that cut injection burden and protect vision from macular edema.]]>Mon, 13 Apr 2026 10:01:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/fda-expands-faricimab-label-to-include-treatment-of-macular-edema-secondary-to-retinal-vein-occlusion-beyond-6-monthshttps://www.modernretina.com/view/fda-expands-faricimab-label-to-include-treatment-of-macular-edema-secondary-to-retinal-vein-occlusion-beyond-6-months<![CDATA[]]>Fri, 10 Apr 2026 14:01:36 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/ocugen-completes-dosing-early-in-phase-2-3-gardian3-trial-for-stargardt-diseasehttps://www.modernretina.com/view/ocugen-completes-dosing-early-in-phase-2-3-gardian3-trial-for-stargardt-disease<![CDATA[The ongoing GARDian3 study is designed to assess whether a single subretinal administration of OCU410ST can slow structural disease progression in patients with ABCA4-associated retinopathy.]]>Fri, 10 Apr 2026 10:02:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/tattoo-associated-uveitis-an-emerging-eye-health-challengehttps://www.modernretina.com/view/tattoo-associated-uveitis-an-emerging-eye-health-challenge<![CDATA[Tattoo ink inflammation increasingly triggers uveitis, often harming vision and requiring systemic steroids.]]>Fri, 10 Apr 2026 10:01:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/directional-oct-provides-biomarkers-of-parkinson-s-disease-in-the-outer-retinahttps://www.modernretina.com/view/directional-oct-provides-biomarkers-of-parkinson-s-disease-in-the-outer-retina<![CDATA[Images showed that Parkinson’s disease is associated with a thicker photoreceptor nuclear layer and a thinner layer of photoreceptor processes.]]>Wed, 08 Apr 2026 10:01:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/fda-grants-rmat-designation-to-rtx-015-optogenetic-gene-therapy-for-retinitis-pigmentosahttps://www.modernretina.com/view/fda-grants-rmat-designation-to-rtx-015-optogenetic-gene-therapy-for-retinitis-pigmentosa<![CDATA[FDA fast-tracks RTx-015, an optogenetic gene therapy aiming to restore vision in late-stage retinitis pigmentosa.]]>Tue, 07 Apr 2026 17:45:42 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/merck-launches-phase-2b-3-malbec-trial-of-mk-8748-in-wet-amdhttps://www.modernretina.com/view/merck-launches-phase-2b-3-malbec-trial-of-mk-8748-in-wet-amd<![CDATA[MALBEC (NCT07440225) is a randomized, double-masked trial evaluating the safety and efficacy of MK-8748 at 2 dose levels versus control (aflibercept 2mg).]]>Mon, 06 Apr 2026 18:08:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/oln324-shows-comparable-vision-gains-potential-durability-advantage-vs-faricimab-in-phase-1b-wamd-dme-studyhttps://www.modernretina.com/view/oln324-shows-comparable-vision-gains-potential-durability-advantage-vs-faricimab-in-phase-1b-wamd-dme-study<![CDATA[In the JADE trial, OLN324 demonstrated numerically greater visual acuity gains and evidence of sustained retinal drying with fewer retreatments during a treatment-free follow-up period, compared with faricimab.]]>Mon, 06 Apr 2026 13:12:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/fda-approves-extended-dosing-intervals-up-to-20-weeks-for-eylea-hd-in-wamd-and-dmehttps://www.modernretina.com/view/fda-approves-extended-dosing-intervals-up-to-20-weeks-for-eylea-hd-in-wamd-and-dme<![CDATA[]]>Fri, 03 Apr 2026 17:35:10 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/getting-to-the-root-of-geographic-atrophy-diagnosis-and-managementhttps://www.modernretina.com/view/getting-to-the-root-of-geographic-atrophy-diagnosis-and-management<![CDATA[Three real-world GA cases reveal why early imaging-guided treatment matters, how fast vision can decline, and how to manage CNV risk with anti-VEGF.]]>Fri, 03 Apr 2026 10:01:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/first-patient-dosed-in-phase-i-ii-trial-of-complement-targeting-gene-therapy-for-geographic-atrophyhttps://www.modernretina.com/view/first-patient-dosed-in-phase-i-ii-trial-of-complement-targeting-gene-therapy-for-geographic-atrophy<![CDATA[The Opti-GAIN study from Complement Therapeutics is assessing the safety, tolerability, and preliminary efficacy in GA secondary to age-related macular degeneration (AMD) of CTx001.]]>Thu, 02 Apr 2026 12:53:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/taking-a-step-beyond-low-vision-aids-to-sharpen-the-focus-on-visual-rehabilitationhttps://www.modernretina.com/view/taking-a-step-beyond-low-vision-aids-to-sharpen-the-focus-on-visual-rehabilitation<![CDATA[Study finds low-vision rehab boosts daily function and quality of life, but exposes gaps in long-term data and diverse research.]]>Wed, 01 Apr 2026 15:08:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/aflibercept-to-treat-rop-in-extremely-low-birth-weight-childrenhttps://www.modernretina.com/view/aflibercept-to-treat-rop-in-extremely-low-birth-weight-children<![CDATA[Aflibercept briefly reverses severe ROP in tiny preemies, yet nearly half relapse within weeks—prompting laser rescue and renewed safety questions.]]>Mon, 30 Mar 2026 10:00:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/multi-luminance-shape-discrimination-test-shows-reliability-in-low-vision-rp-populationhttps://www.modernretina.com/view/multi-luminance-shape-discrimination-test-shows-reliability-in-low-vision-rp-population<![CDATA[New MLSDT functional vision test tracks advanced retinitis pigmentosa better than acuity, supporting future gene and optogenetic therapy endpoints.]]>Fri, 27 Mar 2026 12:00:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/phase-2-topline-data-ocugen-ocu410-reduces-geographic-atrophy-lesion-growth-by-31-at-12-monthshttps://www.modernretina.com/view/phase-2-topline-data-ocugen-ocu410-reduces-geographic-atrophy-lesion-growth-by-31-at-12-months<![CDATA[Phase 2 ArMaDa data show statistically significant 31% reduction in GA lesion growth with OCU410 at 12 months, with a favorable safety profile supporting phase 3 development.]]>Tue, 24 Mar 2026 16:15:05 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/the-retina-tl-dr-with-dr-weng-moving-beyond-anti-vegf-with-otx-tki-and-pravin-u-dugel-mdhttps://www.modernretina.com/view/the-retina-tl-dr-with-dr-weng-moving-beyond-anti-vegf-with-otx-tki-and-pravin-u-dugel-md<![CDATA[In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Dugel about the novel hydrogel-based tyrosine kinase inhibitor platform designed to extend durability and improve long-term outcomes in neovascular AMD. ]]>Mon, 23 Mar 2026 04:00:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/onl-therapeutics-randomizes-first-european-patient-in-phase-2-ga-trial-of-xelafaslatidehttps://www.modernretina.com/view/onl-therapeutics-randomizes-first-european-patient-in-phase-2-ga-trial-of-xelafaslatide<![CDATA[The trial, sponsored by ONL Therapeutics, aims to enroll approximately 324 patients across sites in Europe, the United States, and Canada.]]>Mon, 16 Mar 2026 14:45:46 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/genetic-retinoblastoma-risk-stratified-by-age-among-patients-with-metachronous-bilateral-conversionhttps://www.modernretina.com/view/genetic-retinoblastoma-risk-stratified-by-age-among-patients-with-metachronous-bilateral-conversion<![CDATA[Study shows RB1-positive infants diagnosed before 9 months face higher fellow-eye retinoblastoma risk, guiding smarter surveillance and de-escalation.]]>Fri, 13 Mar 2026 19:00:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/galimedix-therapeutics-earns-milestone-payment-in-ophthalmology-partnership-with-th-a-open-innovationhttps://www.modernretina.com/view/galimedix-therapeutics-earns-milestone-payment-in-ophthalmology-partnership-with-th-a-open-innovation<![CDATA[The successful completion and the milestone payment “provide Galimedix with an important operational runway to proceed with plans for additional clinical development in Alzheimer’s disease and other indications."]]>Fri, 13 Mar 2026 14:15:01 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/ophthalmic-drug-shortages-more-frequent-longer-lasting-than-averagehttps://www.modernretina.com/view/ophthalmic-drug-shortages-more-frequent-longer-lasting-than-average<![CDATA[US eye medication shortages make up a sizable share of active drug shortages and last longer, driven by manufacturing issues, weak generics and unclear causes.]]>Fri, 13 Mar 2026 14:15:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/johnson-johnson-s-tecnis-puresee-edof-iol-cleared-for-us-markethttps://www.modernretina.com/view/johnson-johnson-s-tecnis-puresee-edof-iol-cleared-for-us-market<![CDATA[The manufacturer notes that TECNIS PureSee is the first US EDOF IOL cleared by the FDA without contrast sensitivity cautions.]]>Thu, 12 Mar 2026 14:15:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/eichenbaum-acorns-collaborative-retina-care-with-jeffrey-gerson-odhttps://www.modernretina.com/view/eichenbaum-acorns-collaborative-retina-care-with-jeffrey-gerson-od<![CDATA[For Jeffry D. Gerson, OD, FAAO, an early fascination with retinal disease—sparked during residency and shaped by mentorship and emerging OCT technology—led to a career focused on education and OD-MD collaboration.]]>Wed, 11 Mar 2026 12:00:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/novabridge-visara-report-positive-phase-2a-results-for-dual-vegf-a-ang-2-inhibitor-vis-101https://www.modernretina.com/view/novabridge-visara-report-positive-phase-2a-results-for-dual-vegf-a-ang-2-inhibitor-vis-101<![CDATA[The phase 2a study looks at retinal vascular diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).]]>Wed, 11 Mar 2026 10:55:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/fda-clears-phase-i-ii-trial-of-svt-001-cell-therapy-for-familial-drusen-associated-vision-losshttps://www.modernretina.com/view/fda-clears-phase-i-ii-trial-of-svt-001-cell-therapy-for-familial-drusen-associated-vision-loss<![CDATA[FDA greenlights first human trial of SVT-001, a regenerative cell therapy aiming to restore vision for patients with rare familial drusen.]]>Tue, 10 Mar 2026 15:53:10 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/ocugen-completes-enrollment-in-limelight-phase-3-trial-of-ocu400-for-retinitis-pigmentosahttps://www.modernretina.com/view/ocugen-completes-enrollment-in-limelight-phase-3-trial-of-ocu400-for-retinitis-pigmentosa<![CDATA[]]>Tue, 10 Mar 2026 15:50:27 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/pegcetacoplan-does-not-impact-anti-vegf-treatment-in-geographic-atrophy-with-ted-leng-md-mshttps://www.modernretina.com/view/pegcetacoplan-does-not-impact-anti-vegf-treatment-in-geographic-atrophy-with-ted-leng-md-ms<![CDATA[Leng discusses preliminary results from an ongoing study investigating the interaction between pegcetacoplan and anti-VEGF treatments in patients with GA.]]>Tue, 03 Mar 2026 19:30:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/eylea-8mg-in-rvo-quasar-clinical-perspectives-videohttps://www.modernretina.com/view/eylea-8mg-in-rvo-quasar-clinical-perspectives-video<![CDATA[]]>Tue, 03 Mar 2026 16:00:16 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/eylea-8mg-in-rvo-snapshot-of-the-64-week-quasar-datahttps://www.modernretina.com/view/eylea-8mg-in-rvo-snapshot-of-the-64-week-quasar-data<![CDATA[]]>Tue, 03 Mar 2026 15:01:35 GMTModern RetinausModern Retina Articles